Table 5.

Current CAR NK therapy clinical trials (registered in clinicaltrials.gov)

Target antigen	Cancer	Structure	Phase	NK source	NCT
Hematological malignancies
CD19	Refractory B NHL Refractory B SLL Relapse adult ALL Relapse CLL Relapse NHL	CD19.CAR-aNKT.IL15	I	N/R	NCT03774654
CD22	R/R B lymphoma	N/R	I	N/R	NCT03692767
CD19	R/R B lymphoma	N/R	I	N/R	NCT03690310
CD19	R/R NHL	N/R	I	N/R	NCT04639739
CD19/CD22	R/R B lymphoma	N/R	I	N/R	NCT03824964
CD19	B cell lymphoma	CD19-CD28-2A-iCasp9-IL15	I/II	Cord blood	NCT03579927 (withdrawn)
CD19	B cell lymphoma malignancy ALL CLL	CD19-iCasp9-IL15	I/II	UCB NK cell	NCT03056339
CD33	AML	ScFv-CD28-CD137-CD3ζ	I/II	NK92	NCT02944162
BCMA	R/R multiple myeloma	N/R	I/II	NK92	NCT03940833
CD7	Lymphoma	ScFv-CD28-CD137- CD3ζ	I/II	NK92	NCT02742727
CD19	Lymphoma ALL	N/R	I/II	N/R	NCT04727093
NKG2DL	AML MDS	N/R	I	Allogeneic	NCT04623944
CD19	B-ALL	ScFv-CD8αTM-CD137- CD3ζ	II	PBNK	NCT01974479
CD19	Lymphoma Leukemia	ScFv-CD28-CD137- CD3ζ	I/II	NK92	NCT02892695
CD19	B cell lymphoma	iCasp9-ScFv-CD28- CD3ζ-IL15	I/II	UCB NK	NCT03056339
CD19	B cell lymphoma CLL	ScFv-NKG2D-2B4- CD3ζ-IL15/R-hnCD16	I	iPSC(FD596)	NCT04245722
CD19	ALL	CAR-19-4IB- CD3ζ	I	Hoploidentical donor	NCT00995137
Solid malignancies
GD2	Neuroblastoma	iC9-GD2.CD28.OX40- ζ	I	PBMC	NCT02439788 (withdrawn)
GD2	Neuroblastoma	GD2-CD28. Ζ.IL15	I	PB NK	NCT03294954
PSML	Prostatic cancer	N/R	I	N/R	NCT03692663
NKG2DL	Metastatic solid tumor	ScFv-CD8αTM- CD3ζ ScFv-CD8αTM- DAP12	I	PB NK	NCT03415100
ROBO I	Solid tumor	N/R	I/II	NK92	NCT03940820
Mesothelin	Ovarian cancer	N/R	I	PB NK	NCT03692637
MUC 1	Hepatocellular carcinoma Non-small cell lung cancer Pancreatic cancer TNIBC Glioma Colorectal cancer Gastric cancer	ScFv-CD28-CD137- CD3ζ	I/II	NK92	NCT02839954
ROBO 1	Pancreatic cancer	N/R	I/II	NK92	NCT03942457
HER2	GBM	ScFv-CD28- CD3ζ	I	NK92	NCT03383978
ROBO 1	Solid tumor	N/R	I/II	N/R	NCT03931720